治疗学交叉点：从癌症到自身免疫，扩展 CD19 CAR T 细胞的获益。
Therapeutic intersections: Expanding benefits of CD19 CAR T cells from cancer to autoimmunity.
机构信息
Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.
出版信息
Cell Stem Cell. 2024 Apr 4;31(4):437-438. doi: 10.1016/j.stem.2024.03.006.
Anti-CD19 CAR T cells were among the last decade's scientific breakthroughs, achieving remarkable remissions in patients with B cell leukemias and lymphomas. Now, the engineered cell therapies are traversing disease indications into autoimmunity and resolving disease symptoms in patients with systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis..
抗 CD19 CAR T 细胞是过去十年的科学突破之一，在 B 细胞白血病和淋巴瘤患者中实现了显著的缓解。现在，这些经过基因工程改造的细胞疗法正在跨越自身免疫性疾病的适应症，并在系统性红斑狼疮（SLE）、特发性炎性肌病和系统性硬皮病等自身免疫性疾病患者中解决疾病症状。
Zotero 插件